Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

泊马度胺 危险系数 地塞米松 多发性骨髓瘤 沙利度胺 临床终点 胃肠病学 医学 置信区间 随机对照试验 外科 来那度胺 内科学 肿瘤科
作者
Meletios Athanasios Dimopoulos,Meral Beksaç,Luděk Pour,Sosana Delimpasi,Vladimir I. Vorobyev,Hang Quach,Ivan Špıčka,Jakub Radocha,Pawel J. Robak,Kihyun Kım,Michèle Cavo,Kazuhito Suzuki,Kristin R. Morris,Farrah Pompilus,Amy Phillips-Jones,Xiaoou L Zhou,Giulia Fulci,Neal Sule,Brandon Edward Kremer,Joanna Opalińska
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:391 (5): 408-421 被引量:220
标识
DOI:10.1056/nejmoa2403407
摘要

BACKGROUND: Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple myeloma; however, most patients have a relapse. Frontline lenalidomide therapy has increased the number of patients with lenalidomide-refractory disease at the time of the first relapse. METHODS: In this phase 3, randomized, open-label trial, we evaluated belantamab mafodotin, pomalidomide, and dexamethasone (BPd), as compared with pomalidomide, bortezomib, and dexamethasone (PVd), in lenalidomide-exposed patients who had relapsed or refractory myeloma after at least one line of therapy. The primary end point was progression-free survival. Disease response and safety were also assessed. RESULTS: A total of 302 patients underwent randomization; 155 were assigned to the BPd group, and 147 to the PVd group. At a median follow-up of 21.8 months (range, <0.1 to 39.2), the 12-month estimated progression-free survival with BPd was 71% (95% confidence interval [CI], 63 to 78), as compared with 51% (95% CI, 42 to 60) with PVd (hazard ratio for disease progression or death, 0.52; 95% CI, 0.37 to 0.73; P<0.001). Data on overall survival were immature. The percentage of patients with a response to treatment (partial response or better) was 77% (95% CI, 70 to 84) in the BPd group and 72% (95% CI, 64 to 79) in the PVd group; 40% (95% CI, 32 to 48) and 16% (95% CI, 11 to 23), respectively, had a complete response or better. Grade 3 or higher adverse events occurred in 94% of the patients in the BPd group and 76% of those in the PVd group. Ocular events occurred in 89% of the patients who received BPd (grade 3 or 4 in 43%) and 30% of those who received PVd (grade 3 or 4 in 2%); ocular events in the BPd group were managed with belantamab mafodotin dose modification. Ocular events led to treatment discontinuation in 9% of the patients in the BPd group and in no patients in the PVd group. CONCLUSIONS: Among lenalidomide-exposed patients with relapsed or refractory myeloma, BPd conferred a significantly greater benefit than PVd with respect to progression-free survival, as well as deeper, more durable responses. Ocular events were common but were controllable by belantamab mafodotin dose modification. (Funded by GSK; DREAMM-8 ClinicalTrials.gov number, NCT04484623; EudraCT number, 2018-004354-21.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
落梦发布了新的文献求助10
刚刚
ngyx发布了新的文献求助10
刚刚
晨曦发布了新的文献求助10
1秒前
runrun完成签到,获得积分10
1秒前
大个的应助被十二一字曾采纳,获得10
2秒前
天天快乐的应助被十二一字曾采纳,获得10
2秒前
周周发布了新的文献求助10
3秒前
4秒前
aaa完成签到,获得积分10
5秒前
科研通AI6.3的应助被zgxj采纳,获得10
5秒前
赘婿的应助被buqi采纳,获得50
5秒前
My_magnum_opus的应助被Seorina采纳,获得30
5秒前
6366336发布了新的文献求助10
6秒前
mmma发布了新的文献求助10
8秒前
9秒前
健忘不可完成签到,获得积分10
10秒前
10秒前
10秒前
机智铃铛关注了科研通微信公众号
11秒前
小蘑菇的应助被晨曦采纳,获得10
12秒前
Ava的应助被vy67采纳,获得10
12秒前
viviji完成签到,获得积分10
13秒前
kk完成签到,获得积分10
14秒前
小二郎的应助被愤怒的迎南采纳,获得10
16秒前
cdercder的应助被标致青雪采纳,获得10
16秒前
Tay完成签到 ,获得积分10
16秒前
华仔的应助被just do it采纳,获得10
16秒前
成就的德地完成签到,获得积分10
18秒前
赘婿的应助被水产里的遗传采纳,获得10
19秒前
19秒前
20秒前
20秒前
20秒前
英姑的应助被无私的画笔采纳,获得10
22秒前
幽默玉米完成签到,获得积分10
22秒前
科研通AI6.3的应助被master采纳,获得10
23秒前
暮晓见发布了新的文献求助10
23秒前
23秒前
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183601
求助须知:如何正确求助?哪些是违规求助? 9572875
关于积分的说明 21827816
捐赠科研通 7780716
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558197
邀请新用户注册赠送积分活动 2480485